About:
Curespec offers a medical device solution that treats hypertension and chronic kidney disease (CKD). The company’s technology generates new blood vessels and restores function to damaged tissue. Curespec’s first market-ready product, Nephrospec, is a safe, low-intensity, noninvasive shockwave device intended for the interrelated treatment of hypertension and CKD. Designed to save up to 80% of costs while reducing suffering and needless loss of life, Nephrospec can improve kidney function in weeks, delay onset of dialysis with outpatient treatment, and function as a complementary solution to optimal medical care for hypertension and CKD. Curespec has obtained CE and AMAR approval in Europe and Israel respectively and is a wholly owned subsidiary of Medispec.
Additional:
Nephrospec is a low-intensity extracorporeal shockwave therapy (Li-ESWT) system offering an innovative, safe, non-invasive and painless treatment, reducing the need for medication & Dialysis.
- Atherosclerotic renal artery stenosis (ARAS) remains the leading cause of several renovascular diseases such as Chronic Kidney Disease. ARAS causes hypertension, loss of renal function, and cardiovascular complications.
- Treatment by means of percutaneous transluminal renal artery stenting (PTRAS) is disappointing in preserving renal function and preventing cardiovascular events.
- Microvascular remodeling (rarefaction) is an important pathologic alteration in the stenotic kidney.
- PTRAS cannot repair the pre-existed intrarenal damage.
- RDN (Renal Denervation) reduces BP but does not treat the kidney
Website:
israeltrade.org.au 